CD147-conjugated minocycline nanomicelles (MINO@PNM@CD147) combine anti-inflammatory efficacy with precise brain-targeted delivery, offering a potent and safe nanotherapeutic strategy for mitigating neuroinflammation and promoting recovery after intracerebral hemorrhage.
Key Findings
Results
MINO@PNM@CD147 nanomicelles exhibited uniform spherical morphology with an average hydrodynamic diameter of 13.5 nm and high colloidal stability.
Nanomicelles were synthesized using a co-solvent evaporation method followed by covalent conjugation of CD147 antibodies via amide bond formation.
The formulation demonstrated a uniform spherical morphology with an average hydrodynamic diameter of 13.5 nm.
High colloidal stability was confirmed during physicochemical characterization in vitro.
The system is described as a polymeric nanomicelle platform loaded with minocycline and conjugated with anti-CD147 monoclonal antibodies.
Results
MINO@PNM@CD147 demonstrated excellent cellular compatibility and effective suppression of pro-inflammatory mediators in LPS-activated BV-2 microglial cells in vitro.
Biocompatibility was assessed in vitro as part of physicochemical and targeting efficiency characterization.
The formulation effectively suppressed pro-inflammatory mediators in lipopolysaccharide (LPS)-activated BV-2 cells.
BV-2 cells are a murine microglial cell line commonly used as an in vitro neuroinflammation model.
Excellent cellular compatibility was observed, indicating low cytotoxicity of the nanomicelle formulation.
Results
In vivo fluorescence imaging confirmed targeted accumulation of MINO@PNM@CD147 in perihematomal regions in a collagenase-induced ICH mouse model.
Therapeutic efficacy was evaluated in a collagenase-induced ICH mouse model.
In vivo fluorescence imaging was used to assess biodistribution and targeting efficiency.
Targeted accumulation was confirmed specifically in perihematomal regions, suggesting effective brain targeting via CD147 conjugation.
Non-targeted formulations were used as comparators to assess the contribution of CD147 antibody conjugation to targeting.
Results
MINO@PNM@CD147 treatment markedly reduced neuronal degeneration, microglia and astrocyte activation, leukocyte infiltration, and cell apoptosis following ICH.
Outcomes were assessed using histopathological, biochemical, and behavioral assessments in the ICH mouse model.
Reductions were observed in neuronal degeneration, microglial activation, astrocyte activation, leukocyte infiltration, and cell apoptosis.
The release of inflammatory mediators was significantly attenuated with MINO@PNM@CD147 treatment.
These findings were compared against free minocycline and non-targeted nanomicelle formulations.
Results
MINO@PNM@CD147 administration led to substantial improvements in neurological function compared with free minocycline or non-targeted formulations.
Neurological function was assessed using behavioral assessments in the collagenase-induced ICH mouse model.
Improvements were substantial relative to both free minocycline and non-targeted nanomicelle controls.
The superior efficacy of MINO@PNM@CD147 over non-targeted formulations underscores the functional contribution of CD147-mediated targeting.
The superior efficacy over free minocycline highlights the benefit of the nanomicelle delivery system in improving bioavailability and reducing systemic toxicity.
Background
Minocycline's clinical translation for ICH has been limited by poor aqueous solubility, low bioavailability, and dose-related systemic toxicity, motivating the development of a targeted nanotherapeutic approach.
Minocycline is a broad-spectrum tetracycline antibiotic previously shown to attenuate hematoma expansion, reduce blood-brain barrier disruption, and improve neurological outcomes in preclinical ICH models.
Poor aqueous solubility, low bioavailability, and dose-related systemic toxicity were identified as key barriers to clinical translation.
The CD147-conjugated nanomicelle system was designed specifically to address these pharmacological limitations.
CD147 is expressed on brain endothelial and perihematomal cells, making it a rational target for brain-directed drug delivery after ICH.
What This Means
This research suggests that a new drug delivery system can more effectively treat brain bleeding (intracerebral hemorrhage, or ICH) by getting anti-inflammatory medication directly to the injured area. The researchers took minocycline — an antibiotic known to reduce brain inflammation after ICH but limited by poor solubility and toxicity at higher doses — and packaged it inside tiny nanoparticles (nanomicelles) about 13.5 nanometers in diameter. They then attached antibodies that recognize a protein called CD147, which is found on cells in and around the site of a brain bleed, so the nanoparticles would be drawn specifically to the injured area rather than distributing throughout the body.
In laboratory tests, the nanoparticles were safe for cells and reduced inflammatory signals in immune cells exposed to a bacterial trigger. In mice with induced brain bleeds, imaging confirmed the nanoparticles accumulated at the bleeding site. Treated mice showed significantly less brain cell death, less activation of inflammatory brain cells (microglia and astrocytes), less immune cell invasion, and lower levels of inflammatory molecules compared to mice given plain minocycline or nanoparticles without the targeting antibody. Most importantly, the mice treated with the targeted nanoparticles showed substantially better neurological function and behavioral recovery.
This research suggests that packaging minocycline in CD147-targeted nanoparticles can overcome the drug's previous limitations and deliver it more precisely to where it is needed after a brain bleed. The approach reduced brain inflammation and improved recovery more effectively than existing formulations in animal models, representing a potentially promising platform for developing new treatments for one of the most deadly and difficult-to-treat forms of stroke. Further studies in larger animals and eventually humans would be needed to determine whether these benefits translate to clinical settings.
Liu Y, Chen Y, Liu Y, Li Z, Wang Q, Yong V, et al.. (2026). CD147-Conjugated Minocycline Nanomicelles Alleviate Neuroinflammation and Improve Neurological Function Following Intracerebral Hemorrhage.. CNS neuroscience & therapeutics. https://doi.org/10.1002/cns.71069